Literature DB >> 32779007

Self-Reported Trismus: prevalence, severity and impact on quality of life in oropharyngeal cancer survivorship: a cross-sectional survey report from a comprehensive cancer center.

Richard C Cardoso1, Mona Kamal1, Jhankruti Zaveri1, Mark S Chambers1, G Brandon Gunn1, Clifton D Fuller1, Stephen Y Lai1, Frank E Mott1, Holly McMillan1, Katherine A Hutcheson2.   

Abstract

OBJECTIVE: The purpose of this study was to estimate prevalence/severity of self-reported trismus, determine association with quality of life (QOL), and examine clinical risk factors in a large population of patients treated for oropharyngeal cancer.
MATERIALS AND METHODS: A cross-sectional survivorship survey was conducted among patients who completed definitive treatment for oropharyngeal carcinoma, disease-free ≥ 1-year post-treatment (median survival, 7 years among 892 survivors). Associations between trismus and QOL were also analyzed using MDASI-HN, EQ-5D, and MDADI. Dietary and feeding tube status were also correlated to trismus status.
RESULTS: Trismus was self-reported in 31%. Severity of trismus positively correlated (r = 0.29) with higher mean interference scores reflecting a moderate association with quality of life (p < 0.0001). There was a negative correlation for MDADI composite scores (r = - 0.33) indicating increased perceived dysphagia related to trismus severity (p < 0.0001). EQ-5D VAS scores were also negatively correlated with trismus severity (r = - 0.26, p < 0.0001). Larger T-stage (p ≤ 0.001), larger nodal stage (p = 0.03), tumor sub-site (p = 0.05), and concurrent chemoradiation (p = 0.01) associated with increased prevalence of trismus. Diet negatively correlated (r = - 0.27) with trismus severity (p = < 0.0001), and survivors with severe trismus were also more likely to be feeding tube-dependent.
CONCLUSION: Severity of trismus appears to negatively impact quality of life and associate with various adverse functional outcomes in long-term oropharyngeal cancer survivorship. Trismus remains associated with advanced disease stages, tumor sub-site (tonsil), and addition of chemotherapy. Further investigation is merited for the dose-effect relationship to the muscles of mastication.

Entities:  

Keywords:  Head and neck cancer; Limited mouth opening; Oropharyngeal cancer; Quality of life; Trismus

Mesh:

Year:  2020        PMID: 32779007      PMCID: PMC8790744          DOI: 10.1007/s00520-020-05630-7

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  25 in total

1.  The effects of antitumor irradiation on mandibular opening and mobility: a prospective study of 58 patients.

Authors:  M Goldstein; W G Maxymiw; B J Cummings; R E Wood
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  1999-09

2.  Long-term outcome and morbidity after treatment with accelerated radiotherapy and weekly cisplatin for locally advanced head-and-neck cancer: results of a multidisciplinary late morbidity clinic.

Authors:  Heidi Rütten; Lucas A M Pop; Geert O R J Janssens; Robert P Takes; Simone Knuijt; Antoinette F Rooijakkers; Manon van den Berg; Matthias A Merkx; Carla M L van Herpen; Johannes H A M Kaanders
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-11-20       Impact factor: 7.038

3.  Measuring head and neck cancer symptom burden: the development and validation of the M. D. Anderson symptom inventory, head and neck module.

Authors:  David I Rosenthal; Tito R Mendoza; Mark S Chambers; Joshua A Asper; Ibrahima Gning; Merrill S Kies; Randal S Weber; Jan S Lewin; Adam S Garden; K Kian Ang; Xin S Wang; Charles S Cleeland
Journal:  Head Neck       Date:  2007-10       Impact factor: 3.147

Review 4.  Trismus in head and neck oncology: a systematic review.

Authors:  P U Dijkstra; W W I Kalk; J L N Roodenburg
Journal:  Oral Oncol       Date:  2004-10       Impact factor: 5.337

5.  Factors associated with restricted mouth opening and its relationship to health-related quality of life in patients attending a Maxillofacial Oncology clinic.

Authors:  B Scott; C Butterworth; D Lowe; S N Rogers
Journal:  Oral Oncol       Date:  2007-09-07       Impact factor: 5.337

6.  Maximal mandibular movements and symptoms of mandibular dysfunction in 70-year old men and women.

Authors:  G Agerberg; T Osterberg
Journal:  Sven Tandlak Tidskr       Date:  1974-05

7.  What is a clinically relevant difference in MDADI scores between groups of head and neck cancer patients?

Authors:  Katherine A Hutcheson; Martha P Barrow; Asher Lisec; Denise A Barringer; Kacie Gries; Jan S Lewin
Journal:  Laryngoscope       Date:  2015-11-06       Impact factor: 3.325

8.  The incidence of trismus and long-term impact on health-related quality of life in patients with head and neck cancer.

Authors:  Nina Pauli; Joakim Johnson; Caterina Finizia; Paulin Andréll
Journal:  Acta Oncol       Date:  2012-11-29       Impact factor: 4.089

9.  Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost.

Authors:  Xiaomin Ou; Xin Zhou; Qi Shi; Xing Xing; Youqi Yang; Tingting Xu; Chunying Shen; Xiaoshen Wang; Xiayun He; Lin Kong; Hongmei Ying; Chaosu Hu
Journal:  Oncotarget       Date:  2015-11-10

Review 10.  Prognostic factors associated with a restricted mouth opening (trismus) in patients with head and neck cancer: Systematic review.

Authors:  Sarah J van der Geer; Phillip V van Rijn; Jan L N Roodenburg; Pieter U Dijkstra
Journal:  Head Neck       Date:  2020-06-18       Impact factor: 3.147

View more
  1 in total

1.  Risk factors associated with patient-reported fatigue among long-term oropharyngeal carcinoma survivors.

Authors:  Puja Aggarwal; Katherine A Hutcheson; Ryan P Goepfert; Adam S Garden; Naveen Garg; Frank E Mott; Clifton D Fuller; Stephen Y Lai; Gary Brandon Gunn; Mark S Chambers; Ehab Y Hanna; Erich M Sturgis; Sanjay Shete
Journal:  Head Neck       Date:  2022-01-27       Impact factor: 3.147

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.